NCT06546397 Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair After Induced Abortion
| NCT ID | NCT06546397 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University |
| Condition | Pregnancy Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-05-09 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 200 participants in total. It began in 2024-05-09 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Induced abortion is a common method to terminate pregnancy, but during the operation, it is necessary to dilate the cervix and aspirate the uterine cavity. Repeated induced abortions may increase the risk of uterine damage, leading to cervical stenosis or intrauterine adhesions, thinning of the endometrium, which may affect the implantation of fertilized eggs and the development of embryos, and ultimately may lead to infertility or miscarriage. This study aims to explore the effects of combined estrogen and progesterone on endometrial repair and ovarian function recovery after induced abortion.
Eligibility Criteria
Inclusion Criteria: * Age between 18 years old (inclusive) and 40 years old (inclusive) * Body Mass Index (BMI) ranging from 18.5Kg/㎡ to 23.9Kg/㎡ * Experienced at least 2 abortions or had a missed abortion * Confirmed gestational age of no more than 10 weeks, and the ultrasonic examination within three days prior to the surgery shows a gestational sac (average of three diameters) of at least 1.0cm, with an embryo length of no more than 3.0cm * Normal preoperative examination results as per the "Clinical Diagnosis and Treatment Guidelines and Technical Operation Standards: Family Planning Volume (2017 Revision)" * Capable of regular follow-ups and willing to sign the informed consent form. Exclusion Criteria: * Individuals with contraindications to estrogen and progesterone therapy * History of uterine adhesions confirmed by hysteroscopy, or a history of uterine cavity surgery or uterine malformation correction * Subjects who require placement of an intrauterine device or administration of oral contraceptives or subcutaneous implants after the procedure * Individuals with mental status or cognitive function abnormalities who are unable to cooperate with the treatment process * Subjects who, in the opinion of the investigator, have potential risks or any other factors that may interfere with the study.
Contact & Investigator
Xiuxiu Jiang, Ph.D
PRINCIPAL INVESTIGATOR
Women's Hospital School Of Medicine Zhejiang University
Frequently Asked Questions
Who can join the NCT06546397 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Pregnancy Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06546397 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06546397 currently recruiting?
Yes, NCT06546397 is actively recruiting participants. Contact the research team at jiangxiuxiu0418@zju.edu.cn for enrollment information.
Where is the NCT06546397 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06546397 clinical trial?
NCT06546397 is sponsored by Women's Hospital School Of Medicine Zhejiang University. The principal investigator is Xiuxiu Jiang, Ph.D at Women's Hospital School Of Medicine Zhejiang University. The trial plans to enroll 200 participants.